These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 29548748)
1. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Bai L; Wang A; Zhang Y; Xu X; Zhang X Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748 [TBL] [Abstract][Full Text] [Related]
2. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma. Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327 [TBL] [Abstract][Full Text] [Related]
3. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells. Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577 [TBL] [Abstract][Full Text] [Related]
4. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408 [TBL] [Abstract][Full Text] [Related]
5. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving. Wang DY; Li N; Cui YL Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583 [TBL] [Abstract][Full Text] [Related]
6. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628 [TBL] [Abstract][Full Text] [Related]
7. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1. Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759 [TBL] [Abstract][Full Text] [Related]
8. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238 [TBL] [Abstract][Full Text] [Related]
9. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949 [TBL] [Abstract][Full Text] [Related]
10. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells. Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501 [TBL] [Abstract][Full Text] [Related]
11. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364 [TBL] [Abstract][Full Text] [Related]
12. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo. Li M; Yin J; Mao N; Pan L Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709 [TBL] [Abstract][Full Text] [Related]
14. Fibronectin and Periostin as Prognostic Markers in Ovarian Cancer. Kujawa KA; Zembala-Nożyńska E; Cortez AJ; Kujawa T; Kupryjańczyk J; Lisowska KM Cells; 2020 Jan; 9(1):. PubMed ID: 31936272 [TBL] [Abstract][Full Text] [Related]
15. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer. Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375 [TBL] [Abstract][Full Text] [Related]
16. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells. Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258 [TBL] [Abstract][Full Text] [Related]
17. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. Yin M; Li C; Li X; Lou G; Miao B; Liu X; Meng F; Zhang H; Chen X; Sun M; Ling Q; Zhou R J Surg Oncol; 2011 Jul; 104(1):29-36. PubMed ID: 21416470 [TBL] [Abstract][Full Text] [Related]
18. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy. Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525 [TBL] [Abstract][Full Text] [Related]
19. Notch1 expression correlates with tumor differentiation status in ovarian carcinoma. Wang M; Wang J; Wang L; Wu L; Xin X Med Oncol; 2010 Dec; 27(4):1329-35. PubMed ID: 20012562 [TBL] [Abstract][Full Text] [Related]
20. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling. Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]